Eisai-Therapeutic Portfolios-Therapeutic Portfolio | Cardiovasculars | Company & Drug | Global | 2024
- The document complements our standalone (detailed) company profile (which emphasis on clinical aspects more) by adding the business facet covering overall strategy, Geographical focus, Therapy area evolution within the portfolio, SWOT analysis- and how the company’s business has evolved in the last couple of years.
- The document gives a bird eyes view about the expected sales performance of the company covering the top-performing brands and therapy area focus based on their adopted business strategy. And how the company is fairing compared to its peers and what ranking changes are expected by the end of the forecast period.
Related Market Assessment Reports
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…
